AbbVie's Q3 2023 Financials: Stock Slips, Humira Struggles, and Dividend Hike

AbbVie reported its financial results for the third quarter of 2023, with diluted EPS of $1.00 on a GAAP basis and adjusted diluted EPS of $2.95. Net revenues for the quarter were $13.927 billion, a decrease of 6.0 percent on a reported basis. The company saw decreases in net revenues from its immunology and aesthetics portfolios, while net revenues from its oncology and neuroscience portfolios showed mixed results. AbbVie also raised its adjusted diluted EPS guidance for 2023 and its EPS guidance floor for 2024, and announced a dividend increase of 4.7 percent.